High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
about
H pylori antibiotic resistance: prevalence, importance, and advances in testingShort-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy'Rescue' therapies for the management of Helicobacter pylori infection.Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.Clinical practice: diagnosis and evaluation of dyspepsia.Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Second-line rescue therapy of helicobacter pylori infection.Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.Alternative and rescue treatment regimens for Helicobacter pylori eradication.Helicobacter pylori: the challenge in therapy.Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pyloriHigh-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infectionUpdate on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.Helicobacter pylori "rescue" therapy after failure of two eradication treatments.Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication."Rescue" regimens after Helicobacter pylori treatment failure.Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.The sequential therapy regimen for Helicobacter pylori eradication.Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.Current options for the treatment of Helicobacter pylori.ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.Rescue Therapy for Helicobacter pylori Infection 2012.Third-line rescue therapy for Helicobacter pylori infection.Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori.A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in situ hybridization in formalin-fixed tissue.Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin.7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
P2860
Q24685864-60B65AE0-1505-43AC-B550-B07EF9130306Q33338688-27F7899E-81AF-4D56-A111-DC31BF0CE9F1Q33371187-155A2986-FA75-4C37-B5C2-19C91EE9D506Q33452908-07B4781E-653C-4B7B-B44B-9EE0426C1B76Q33687928-222B35BB-6822-460A-B1DD-2BFCE5E98791Q33727000-010EC55E-DAF9-4BD8-B19B-CE5F48AD597CQ34409114-6D5D52E5-2C94-465B-BF7F-9838EC99DA36Q34636521-A10EFAC4-7A98-4724-9DCF-A33A8997CF87Q34657352-6FDD92BD-34C8-4B5A-8053-4DD0B3E6CB31Q34789141-807E6344-14DA-4DBC-8F52-BB657B205D3DQ34799596-8F73E377-35CA-4073-9152-DDAF44605AD1Q34823645-C5ACF704-28C2-482F-9C54-B410CF42066EQ35498491-0C63FC7B-0D2D-47EE-9BBF-D89AA33729C8Q35841617-B9BD627D-7154-478D-B8F1-ED9F5A3741B3Q36132712-1851C08F-ABF9-41FE-BDDB-DD7254030D9EQ36266517-D51E1A51-EA53-49CA-862A-03876252D294Q36322095-105748EA-9555-462E-BE7F-3AC29DD9EBBCQ37273653-44ADB1CE-28A0-40E2-83F1-79276038CCAEQ37394555-4146A900-246A-4C2B-9023-C79A6B48BDD8Q37646785-5D108180-03C9-4F0B-8880-9FA1DE311B6CQ37703245-40C62C49-6E5B-4C7D-883D-0C77E3026616Q37899929-97D5AE40-B69B-45D2-B90B-3260BF04BA3EQ38075061-4E7463A5-4455-461E-9E72-2F3826B47806Q40378087-DBEDA142-3ACC-463D-A665-62E6714A462CQ40526981-148E3253-91D5-4E4E-992C-5E10EAEBF088Q42129420-E8EDC888-F9E7-4651-ADE9-30A7170CCC26Q42726333-EF0B54D6-3CFB-4EDD-88DA-85B4F055CEB0Q44080544-C4C54F63-FFEC-48C5-AAF0-BC405975F8ADQ44091802-B6988242-4340-4945-8D1F-36DA33F0FDF3Q44488914-942C2F73-1EF0-489D-B8CF-BA127CC6259DQ44505171-EBCC01D4-22B6-4B3F-A94C-65B279B80C3DQ44535163-CFBB90D2-0B90-4EF8-AA42-744FFA59B57AQ44570126-B3D26E1F-8941-41C6-8884-B41A6B8203D6Q44814993-33749262-27CC-4AB5-953F-47538CFAF33BQ46789996-B07D4387-0FD3-4E26-ADF5-D46F74156F81Q46901259-9560ACAE-926F-4643-8822-CDDA2EDBA9B6Q46915097-A8ED38B8-B76A-4757-AFFE-DC316F2F4432Q51052599-A0F91B73-5BA2-4107-A6B4-8A1A17D7F8ADQ54592157-2527D3DB-1B7D-4BCA-AF92-7380B253D56E
P2860
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
High rate of post-therapeutic ...... erapies in a randomized study.
@en
High rate of post-therapeutic ...... erapies in a randomized study.
@nl
type
label
High rate of post-therapeutic ...... erapies in a randomized study.
@en
High rate of post-therapeutic ...... erapies in a randomized study.
@nl
prefLabel
High rate of post-therapeutic ...... erapies in a randomized study.
@en
High rate of post-therapeutic ...... erapies in a randomized study.
@nl
P2093
P2860
P1476
High rate of post-therapeutic ...... erapies in a randomized study.
@en
P2093
A Leodolter
P Malfertheiner
U Von Arnim
Ulrich Peitz
P2860
P304
P356
10.1046/J.1365-2036.2002.01173.X
P407
P577
2002-02-01T00:00:00Z